Core Viewpoint - Company is a major global supplier of tazobactam and has successfully completed the qualification process for downstream customers, which will enhance production capacity and market competitiveness [1] Group 1: Product Supply and Market Position - Company is the largest global supplier of sulbactam and the only domestic supplier certified by international standards, with sulbactam products currently experiencing a price increase [1] - Company is expanding the production capacity of piperacillin, which can be combined with tazobactam and sulbactam to form compound preparations, indicating a broad market demand [1] Group 2: Production Cost and Innovation - Company is one of the few domestic manufacturers with a full industry chain layout for carbapenem products, and the market price for carbapenem products is at a historical low, with limited room for further price declines [1] - Company is collaborating with a research team to develop a continuous flow enzyme method, which is expected to reduce the cost of carbapenem products by 15%-20% [1]

Production Capacity and Expansion Plans - The company currently has a production capacity of 8,000 tons/year for VC products and 4,000 tons/year for FEC products, with plans to increase VC capacity to 10,000 tons/year by Q2 2026 through technical upgrades [2][3] - Future capacity increases for VC and FEC products will depend on market demand and industry capacity releases, with potential targets of 20,000 tons/year for VC and 5,000 tons/year for FEC [2] Impact of Raw Material Price Changes - The price of 6-APA, a key raw material for the company's main pharmaceutical products, has decreased by 38% as of November 3, 2025, which is expected to enhance the gross margin of the pharmaceutical manufacturing business [3] - The company's pharmaceutical products, including Hezobactam and Shubactam, account for approximately 40% of total revenue in 2024 [3] Growth Opportunities in Pharmaceutical Business - The company is a major global supplier of Hezobactam and has successfully completed supplier qualification for its new production process, which is expected to reduce production costs and improve market competitiveness [4] - As the largest supplier of Shubactam, the company is experiencing a price increase trend for this product [4] - The company is expanding the production capacity of Piperacillin, which is a mainstream product with broad market demand [4] Synthetic Biology and Microbial Protein Initiatives - The company has become a pioneer in the domestic microbial protein industry, achieving a production capacity of 1,000 tons/year for filamentous fungal protein and is accelerating the construction of a project with an annual capacity of 200,000 tons for microbial protein and resource utilization [6] - The company has developed a new production strain with independent intellectual property rights and has applied for patents in nine countries, achieving international advanced levels in key production technologies [6][7] - The company’s microbial protein has received multiple international certifications, including HALAL and KOSHER, and is set to expand its market presence upon receiving new food ingredient registration [7][8] Environmental and Economic Benefits - The production process for the new protein not only efficiently converts raw materials but also produces high-value products like amino acid water-soluble fertilizers, contributing to cost reduction and economic benefits [8] - The company aims for zero emissions in its production processes, aligning with green manufacturing goals [8]

Core Viewpoint - Fuxiang Pharmaceutical is expanding the production capacity of Piperacillin, which is a mainstream product in the market with broad demand [1] Group 1 - The company is focusing on increasing the capacity for Piperacillin production [1] - Piperacillin can be combined with Tazobactam and Sulbactam to form compound preparations, making it a popular choice in the market [1] - The demand for these products is significant, indicating a strong market opportunity for the company [1]

Financial Performance - The company reported an increase in mid-year performance compared to last year, but remains in a loss state [2] - Future strategies will focus on improving net profit through various products and avenues [2] Pharmaceutical Manufacturing - The decline in raw material prices for 6-APA and the recovery in prices for the key intermediate 4-AA will enhance the gross margin of the pharmaceutical business [3] - Successful completion of supplier qualification for the new process product, Tazobactam, is expected to reduce production costs and improve market competitiveness [3] - Expansion of Piperacillin production capacity is underway, with significant market demand for combination formulations [3] - New compound formulations are being launched, which will drive demand for related products [3] New Energy Business - The company leads in the industry for lithium battery electrolyte additives in terms of shipment volume and cost control [3] - Current prices for these additives are at historical lows, with limited room for further decline; a price rebound could significantly enhance profits [3] Synthetic Biology - The company is a pioneer in microbial protein production, with significant advancements in core strains, production technology, and market access [4][5] - The registration application for the new protein as a food ingredient has been accepted, with expectations for approval in the second half of the year [4][9] - The company is constructing a project with an annual capacity of 200,000 tons of microbial protein, aiming for a production scale of 20,000 tons of microbial protein and 50,000 tons of amino acid water-soluble fertilizer [5][15] Quality and Certification - The new protein has received multiple international certifications, including HALAL and KOSHER, and has passed various food safety management system certifications [6] - The company has developed proprietary strains and achieved international advanced levels in production technology [5][6] Market Expansion and Collaboration - Strategic partnerships have been established with various companies in the microbial protein sector, enhancing market penetration [11] - The company plans to build an open commercial transformation platform to accelerate product commercialization and brand development [10] Product Development - The new protein can be applied in various sectors, including plant-based meat alternatives, protein drinks, and health products [12] - The company is actively developing new applications and has created several product samples for market introduction [12] Environmental and Regulatory Compliance - The company’s production processes aim for zero emissions and align with national agricultural reduction goals [7][14] - The amino acid water-soluble fertilizer is positioned to meet growing market demands due to regulatory support for green products [15]